Summary of Health Consumer Organisations supported by Medicines Australia Member Companies

Company: Eli Lilly Australia

For the period: 1 January 2022 - 31 December 2022

Name of Health Consumer Organisation	Description of and/or purpose of support	Nature of support (monetary value or equivalent) or description of non-financial support
Pink Hope Community Ltd	Sponsorship of a table for 10 Lilly employees at Pink Hope's 10th Anniversary Impact Dinner (17 June 2022).	\$2,750
Pink Hope Community Ltd	Sponsorship of a patient education series comprising of evidence-based content covering a range of topics that help to educate and empower women when it comes to their health. Content will be released from November 2022 to June 2023.	\$20,500
	Sponsorship of Migraine & Headache Awareness Week (September 19 - 23). The week promotes awareness, education and advocacy with a media supported series of webinars, videos and headache specialists available to patients for free.	
Brain Foundation (Migraine & Headache Australia)		\$12,000
Diabetes Australia	Sponsorship of Diabetes Australia's report 'Unite For Change: Reducing The Impact Of The Diabetes Epidemic' launched on World Diabetes Day 2022.	\$35,000
	Gold level sponsorship of Patient Voice Initiative (PVI) activities in 2022 including: Consumer Online Toolkit Supporting Patient Engagement and Knowledge through Efficient Resource Search (SPEAKERS) Consumer Comment support Patient Voice Training Consumer Conversations Promoting the use of Patient Based Evidence	
Patient Voice Initiative	• Industry Dialogues	\$15,000
Australian Diabetes Educators Association (ADEA)	Collaboration on the Credentialed Diabetes Educator (CDE) of the Year Awards 2022.	\$42,000
	Sponsorship of CanForum 2022 a national forum that examines the key issues confronting the Australian cancer community including: • The in-person and live-streamed event taking place at Parliament House on Tuesday, September 6, 2022. • Sponsorship of a new report developed by Rare Cancers Australia and Canteen which will be launched at the event, titled 'Counting the cost: the true value of	
Rare Cancers Australia	investing in cancer treatment'.	\$30,000